Purchase Order 75N98026P00045
Award Date 2/28/26
Potential Completion Date 2/27/29
Potential Value $60K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10119, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
3
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award, worth $38,745.00, was issued by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Caerus US 1 Inc., operating as Citeline. The contract provides TRIALTROVE licenses to the NCI, which offers pharmaceutical information, drug development data, and market intelligence to support the agency's healthcare research and drug development initiatives. The contract is a firm fixed-price purchase order with an ultimate...
- This is a $18,900.00 firm fixed-price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Caerus US 1 Inc., a for-profit organization, for software. The contract has a completion date of October 24, 2024. The award was made on April 25, 2024, and no set-aside was used. Caerus US 1 Inc., operating as Citeline, is a provider of drug, device, company, clinical trial, and market intelligence to federal agencies,...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $18,000 firm fixed price purchase order to Caerus US 1 Inc. for SOFTWARE. The place of performance is New York, NY. The one year contract starts on July 26, 2023 and ends on July 25, 2024. No set aside designation or subcontractors were identified. The National Cancer Institute is a part of NIH focused on cancer research, so this contract is likely to deliver software products or...
- The National Institutes of Health National Cancer Institute awarded a $489,800 firm fixed price purchase order to Biofortis, LLC of Bethesda, Maryland for Clinical and Translational Research Management (CTRM) software subscriptions, maintenance, and development support services. The contract period of performance is from September 8, 2023 through August 25, 2024. CTRM software assists organizations in managing clinical trials and translational research programs by providing functionality for...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded a $489,805 firm fixed price purchase order to Biofortis, LLC. The contract provides for Biofortis Labmatrix clinical and translational research management software subscriptions, maintenance, and development support services over a base period of performance from August 2021 through August 2022. The original solicitation sought these capabilities on a sole source basis from Biofortis to provide...
- The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a one-year, firm fixed price purchase order valued at fourteen thousand four hundred ninety dollars to Certara USA Inc. for software licenses. Certara will provide the licenses to the NIH NCI in support of its mission to conduct and coordinate research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer,...
- The National Cancer Institute (NCI) awarded a $20,000 firm fixed-price purchase order to Sentieon Inc. on March 20, 2026, to renew an annual software license subscription for one year through March 19, 2027. This contract, which carries no set-aside designation, supports the NCI's genomic research capabilities by providing continued access to Sentieon's proprietary bioinformatics and genomic data analysis software. The work will be performed at the NCI's location in Bethesda, Maryland....
- The federal contract award, valued at $10,743.00, was issued by the National Cancer Institute (NCI) to Certara USA Inc., a leading global technology-enabled drug development and drug safety consultancy, for the procurement of software licenses. The contract is a firm-fixed price purchase order with no set-aside designation and an ultimate completion date of August 13, 2025. Certara USA Inc. has received numerous prime contract awards from the NCI, Food and Drug Administration (FDA), and National...
- The National Cancer Institute (NCI) awarded a $55,311,391.18 cost-plus-fixed-fee contract to Technical Resources International, Inc. (TRI) for Drug Development Support for the Cancer Therapy Evaluation Program (CTEP). The contract, which runs through September 30, 2022, provides comprehensive clinical research support services to NCI, including clinical trials execution, regulatory support, research operations, and specialized scientific services. TRI, a minority-owned, woman-owned, and Hispanic...
- This firm fixed-price purchase order was awarded by the National Cancer Institute, a component of the National Institutes of Health, to Biofortis, LLC, a for-profit limited liability company. The $28,355.00 contract is for Biofortis to provide software licenses and maintenance support for the Labmatrix clinical and translational research management (CTRM) system. This specialized software platform tracks research information, biospecimens, and results to support data management needs for...